Observation On The Efficacy Of Buqi Dingshen Decoction In The Treatment Of Patients With Stable Chronic Obstructive Pulmonary Disease And Depression

Purpose:To explore the clinical efficacy and safety of Buqi dingshen Decoction in the treatment of COPD with depression,and to explore new ideas and methods for the treatment of COPD with depression by traditional Chinese medicine.Material and method:Patients were selected from October 2018 to April 2019 at the outpatient department of the Department of Respiratory Medicine of the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,and met the diagnostic criteria of stable state of COPD with depression(syndrome types of feipi qixu and xinshen shiyang).According to the inclusion and exclusion criteria,72 patients who met the requirements were selected,and the patients were randomly divided into a control group and a treatment group,with 36 patients in each group.Both groups of patients were given Basic intervention,the specific contents were: education and management of COPD(including urging patients to quit smoking,popularizing knowledge about COPD disease,and avoiding exposure to inhaled dust,smoke,and harmful gases,etc.);Aim at the patient's depression symptoms through listening,explaining,comforting and encouraging methods to fully communicate with the patient.Once a week,a total of 4 times.The control group was supplemented with Chinese medicine placebo on the basis of Basic intervention.The appearance,smell,dosage and taking method of the placebo were the same as Buqi Dingshen Decoction in the treatment group;the treatment group was treated with Buqi Dingshen Decoction on the basis of Basic intervention,daily 1 dose,decoction of 300 ml per dose,and take it warmly in the morning,middle and supper half an hour after dinner.The course of treatment was 4 weeks and the follow-up time was 2 weeks.Before the test and 2 weeks after the treatment,4 weeks after the treatment and 2 weeks after the discontinuation of the treatment,TCM syndrome score,HAMD-17 score,CAT score,MMRC score and 6MWD were measured and recorded respectively;and FEV1%pred? FEV1 / FVC% and safety indexes were measured and recorded before the trial and 2 weeks after the discontinuation of the drug.Use Excel to build database.SPSS 23.0 statistical software was used to calculate and analyze the data.Results:1.The final number of cases included in this trial was 69,34 in the control group and 35 in the treatment group.There were no significant differences between the two groups in baseline data such as gender,age,smoking history,Condition(degree of airflow limitation),duration of disease(P> 0.05).2.The total clinical effective rate of treatment with Buqi Dingshen Decoction is obviously better than that of the control group,and the difference is statistically significant(P <0.01).3.The application of Buqi dingshen decoction is significantly better than that of the control group in improving patients' Cough and expectoration,shortness of breath,Uneasy mood,Mental exhaustion and poor appetite,palpitation,insomnia and reducing the total score of TCM symptoms,and the difference was statistically significant(P < 0.05).4.The application of Buqi Dingshen Decoction was significantly superior to the control group in reducing the HAMD-17 score and improving the effect of depression.The difference was statistically significant(P <0.01).5.The treatment with Buqi Dingshen Decoction was significantly better than the control group in reducing the CAT score,mMRC score and increasing 6MWD of the patients,the difference was statistically significant(P <0.05).6.The application of Buqi Dingshen Decoction improved patients' FEV1% pred and FEV1 /FVC% significantly better than the control group,the difference was statistically significant(P <0.01).Conclusion:1.Buqi Dingshen Decoction can significantly improve the TCM syndromes and depression status of patients with chronic obstructive pulmonary disease in the stable phase with depression,and has significant clinical effect and good safety.2.Buqi Dingshen Decoction can significantly reduce the CAT score,mMRC score,and increase of 6MWD in patients with chronic obstructive pulmonary disease with depression,improve pulmonary ventilation function,and improve the quality of life of patients.